Loading viewer...
conference
Format: PDF conference
Revance Therapeutics presented its 2024 strategic priorities and commercial update at the JP Morgan Healthcare Conference, focusing on DAXXIFY® expansion into therapeutics including cervical dystonia, RHA® dermal fillers pipeline growth, and path to positive adjusted EBITDA. The presentation covers commercialization strategy, market opportunities, and financial guidance for 2024.
investor_presentation
106 Pages
conference
24 Pages
Bank of England
First Quantum Minerals Q2 2016 Conference Call
conferenceconference
23 Pages
First Quantum Minerals
SS&C Technologies 2022 Needham Virtual Growth Conference
conferenceconference
23 Pages
SS&C Technologies Holdings, Inc.
Lightpath Technologies 2017 Roth Conference Presentation
conferenceconference
22 Pages
LightPath Technologies